Short answer
Journey Medical Corp (DERM) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $16M (up 21.2% year over year) with net income of −$2M.
Q1 2026 key financials · XBRL
- Revenue
- $16M
- +21.2% YoY
- Net income
- −$2M
- +45.2% YoY
- Operating margin
- -9.4%
- EPS (diluted)
- −$0.08
- +55.6% YoY
Source: XBRL data from the Journey Medical Corp (DERM) Q1 2026 10-Q on SEC EDGAR. USD.
Journey Medical Corp Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $16.0M, up 21% YoY from $13.1M, driven by Emrosi sales
- Emrosi revenue $6.3M, up 202% YoY; weakest foam franchise revenue $1.1M, down 31%
- Operating loss $1.5M vs $3.3M YoY; operating margin -9.3% vs -25.3%
- Cash $27.2M vs $24.1M at December 31; operating cash flow $2.9M vs $(2.8)M YoY
- Going-concern doubt; potential debt or equity financing amid recurring losses and generic competition risks
Risk Factors
- Risk disclosures unchanged from 2025 Form 10-K, with no newly added quarterly risk identified
- Unknown additional risks potentially materially adverse to business, financial condition, or results
- No unregistered equity sales during the reporting period
- No senior-securities defaults reported during the reporting period
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Journey Medical Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.